Therefore, GnRH-targeted cisplatin enhanced the anti-tumoral effect of this drug in an animal model of ovarian cancer, decreasing the size of the tumor xenografts (approximately 40% less volume at day 25, compared to nanogels with only cisplatin) and increasing the survival rate of the animals (60% vs 15% respectively) (80). The gene discussed is GNRH1; the disease is ovarian cancer.